BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg reported routine equity compensation and related tax withholding. On March 16, 2026, he received 19,150 shares of common stock as a grant and a stock option for 45,600 shares at a $57.43 exercise price, both held directly.

The restricted stock units were granted on March 16, 2026, and the option grant vests 12/48ths on March 16, 2027 and 1/48th monthly thereafter. On March 17, 2026, 1,629 shares of common stock were disposed of at $56.05 per share to cover tax obligations, leaving him with 55,099 common shares directly owned.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Friberg Gregory R

Role EVP, Chief R&D Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,629	$56.05	$91K
Grant/Award	Stock Option (Right to Buy Common Stock)	45,600	$0.00	--
Grant/Award	Common Stock	19,150	$0.00	--

Holdings After Transaction: Common Stock — 55,099 shares (Direct); Stock Option (Right to Buy Common Stock) — 45,600 shares (Direct)

Footnotes (1)

Restricted stock units granted March 16, 2026. Price not applicable. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/18/2026 - 01:39 PM

FAQ

What equity awards did BioMarin (BMRN) EVP Gregory Friberg receive?

Gregory Friberg received a grant of 19,150 shares of BioMarin common stock and a stock option for 45,600 shares at an exercise price of $57.43. Both awards were granted on March 16, 2026 as part of his equity compensation.

How do Gregory Friberg’s new stock options at BioMarin (BMRN) vest?

The 45,600-share stock option grant vests 12/48ths on March 16, 2027, then 1/48th on the 16th of each month thereafter. This schedule spreads vesting over several years, encouraging long-term alignment with BioMarin’s performance.

Why did Gregory Friberg dispose of 1,629 BioMarin (BMRN) shares?

The disposition of 1,629 BioMarin common shares on March 17, 2026 is classified as a tax-withholding transaction. Shares were delivered at $56.05 per share to satisfy tax liabilities, not as an open-market sale for investment reasons.

How many BioMarin (BMRN) shares does Gregory Friberg hold after these transactions?

Following the March 2026 transactions, Gregory Friberg directly owns 55,099 shares of BioMarin common stock. This figure reflects his position after 1,629 shares were disposed of for tax withholding related to his equity compensation.

Are Gregory Friberg’s March 2026 BioMarin (BMRN) transactions open-market trades?

No, the filing shows compensation-related activity: grants of common stock and stock options, plus a tax-withholding disposition of 1,629 shares. There are no open-market purchases or sales reported, and net buy/sell activity is classified as neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friberg Gregory R

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

CALIFORNIA

94901

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2026		A		19,150	A	$0⁽¹⁾	56,728	D
Common Stock	03/17/2026		F		1,629	D	$56.05	55,099	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy Common Stock)	$57.43	03/16/2026		A		45,600		03/16/2027⁽²⁾	03/15/2036	Common Stock	45,600	$0	45,600	D

Explanation of Responses:

1. Restricted stock units granted March 16, 2026. Price not applicable.

2. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR